EGFR and non-small cell lung carcinoma: Several single-arm phase II trials have investigated the efficacy and safety of preoperative use of erlotinib or gefitinib in the neoadjuvant setting for patients with resectable NSCLC with EGFR mutations (Zhong et al., 2019; Zhang et al., 2021) (see Table 1).